Eribulin mesylate

Clinical Cancer Research

Volumn 17, Issue 21, 2011, Pages 6615-6622

  Jain, Sarika ^a   Vahdat, Linda T ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERIBULIN; GEMCITABINE; IXABEPILONE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; VINCA ALKALOID;

ADVANCED CANCER; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST CANCER; COST EFFECTIVENESS ANALYSIS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG COST; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOGLYCEMIA; HYPOPHOSPHATEMIA; KARNOFSKY PERFORMANCE STATUS; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MICROTUBULE ASSEMBLY; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT CARE; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SARCOMA; SOLID TUMOR; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; UROGENITAL TRACT CANCER;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; FURANS; HUMANS; KETONES; MESYLATES;

EID: 80455173478     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1807     Document Type: Review

References (28)

1. American Cancer Society. Atlanta (GA): American Cancer Society. Cancer Facts and Figures 2011. Available from: http://www.cancer. org/acs/groups/ content/@epidemiologysurveilance/documents/document/acspc-029771.pdf.
2. Bai RL, Paull KD, Herald CL, Malspeis L, Pettit GR, Hamel E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 1991;266:15882-9. (Pubitemid 21907740)
3. Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001;61:1013-21. (Pubitemid 32174419)
4. Aicher TD, Buszek KR, Fang FG, Forsyth CJ, Jung SH, Kishi Y, et al. Total synthesis of halichondrin B and norhalichondrin B. J Am Chem Soc 1992;114:3162-4.
5. Nogales E. Structural insights into microtubule function. Annu Rev Biochem 2000;69:277-302.
6. Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004;64:5760-6. (Pubitemid 39095575)
7. Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4:1086-95. (Pubitemid 41079102)
8. Alday PH, Correia JJ. Macromolecular interaction of halichondrin B analogues eribulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugation. Biochemistry 2009;48:7927-38.
9. Agoulnik S, Kuznetsov G, Tendyke K, Parent LA, Marsh JP, Twine N, et al. Sensitivity to halichondrin analog E7389 and hemiasterlin analog E7974 correlates with bIII tubulin isotype expression in human breast cancer cell lines. J Clin Oncol 2005;23(16S):2012.
10. Synold TW, Morgan RJ, Newman EM, Lenz HJ, Gandara DR, Colevas AD, et al. A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: a California Cancer consortium trial. J Clin Oncol 2005;23[Suppl]:3036.
11. Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 2009;15:4207-12.
12. Tan AR, Rubin EH, Walton DC, Shuster DE, Wong YN, Fang F, et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 2009;15: 4213-9.
13. Witteveen P, Marchetti S, Mergui-Roelvink M, Reyderman L, Copalu W, Wanders J, et al. Eribulin mesylate pharmacokinetics in patients with hepatic impairment. J Clin Oncol 2010;28 (suppl):2582.
14. Devriese L, Wanders J, Jenner A, Edwards G, Reyderman L, Copalu W, et al. Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole [abstract 574]. EORTC-NCI- AACR Symposium 2010;8:181.
15. Zheng W, Seletsky B, Palme M, Habgood G, Singer L, Dipietro L. Structure-activity relationships of synthetic halicondrin B analog E7389: in vitro susceptibility to PgP- mediated drug efflux. Proc Am Assoc Cancer Res 2003;7:2751.
16. Kuznetsov G, TenDyke K, Yu M, Littlefield B. Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 22-26 Oct 2007; San Francisco, (CA); abstract C58.
17. Minami H, Mukohara T, Nagai S, Mukai H, Namiki M. A phase I study of eribulin mesylate (E7389) in patients with refractory cancers. Eur J Cancer 2008;6(Suppl):140.
18. Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009;27:2954-61.
19. Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roché H, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010;28:3922-8.
20. Iwata H, Aogi K, Masuda N, Mukai H, Yoshida M, Rai Y, et al. Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer [abstract]. J Clin Oncol 2010;28:1081.
21. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011;377:914-23.
22. Twelves C, Cortes J, Vahdat LT, Wanders J, Akerele C, Kaufman PA. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer 2010;10:160-3.
23. Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407-14. (Pubitemid 47310876)
24. Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010;28:3256-63.
25. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23: 7794-803. (Pubitemid 46657376)
26. Medicare Part B Drugs Average Sales Price. 2011 ASP Drug Pricing Files. www.cms.gov/home/medicare.asp. Jul 2011. ASP Pricing File 061611.xls. [Accessed June 21, 2011].
27. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine. Available from: www.ClinicalTrials.gov.
28. Conde C, Cáceres A. Microtubule assembly, organization and dynamics in axons and dendrites. Nat Rev Neurosci 2009;10:319-32.